ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
Detecting circulating tumor DNA after lung cancer surgery may help predict which patients remain at high relapse risk.
Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment 1-3 . Here, we present the first report of prespecified secondary endpoints of event-free survival (EFS) and circulating tumour DNA (ctDNA) clearance, and exploratory analyses of associations between ctDNA dynamics and clinical outcomes.
What the study was
- Study design
- Randomized clinical trial
- Population
- Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment 1-3 .
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Nature
Why it surfaced
Randomized clinical trial with a PubMed abstract reviewed; the 7/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.